Heidelberg, Germany; April 29 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series C financing round of ¬ 20 million. The proceeds from this transaction will be used to fund the clinical validation of (…)
[Read article]
[Source: BioSpace]
10.03.2010 - In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical (…)
[Read article]
[Source: Bionity.com]
Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful completion of the preclinical development of its lead product AFM 13 for the treatment of Hodgkin's lymphoma. Following promising preclinical (…)
[Read article]
[Source: BioSpace]
Heidelberg, Germany; January 14 2010: Affimed Therapeutics AG, the therapeutic antibody company from Heidelberg, announced today that it is now concentrating all activities on the exclusive development of its in-house drug candidates derived from the company's proprietary (…)
[Read article]
[Source: BioSpace]
NEW YORK, Oct. 26 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment (…)
[Read article]
[Source: PR Newswire]
NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024 (…)
[Read article]
[Source: Business Wire]
Heidelberg, Germany, September 15, 2009 - Affimed Therapeutics AG announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the human recombinant antibody AFM13 for the treatment of Hodgkin lymphoma. The designation entitles Affimed (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1d5546/therapeutic_monocl) has announced the addition of the "Therapeutic Monoclonal Antibodies Markets" report to their offering. Newly published Therapeutic Monoclonal Antibodies Markets (…)
[Read article]
[Source: Business Wire]
NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Therapeutic Monoclonal Antibodies Markets (…)
[Read article]
[Source: Business Wire]
11.02.2009 - Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education (…)
[Read article]
[Source: Bionity.com]
Heidelberg, Germany - February 09, 2009 - Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and (…)
[Read article]
[Source: BioSpace]
LONDON, UNITED KINGDOM-(Marketwire - Oct. 6, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 (…)
[Read article]
[Source: Marketwire]
10 Jun 2008 - Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial (…)
[Read article]
[Source: Bionity.com]
Heidelberg, Germany June 05, 2008 Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where (…)
[Read article]
[Source: BioSpace]
14 May 2008 - Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other (…)
[Read article]
[Source: Bionity.com]
HEIDELBERG, Germany-(BUSINESS WIRE)-Affimed Therapeutics, AG, a leading developer of next generation antibody therapeutics, today announced a second closing of Euro 5 million to its Series B funding. This addition increases the total for the round to Euro 30 million (USD 45 (…)
[Read article]
[Source: Business Wire]
OSLO, Norway-(BUSINESS WIRE)-The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company s growth, Dr. Kiprijanov brings (…)
[Read article]
[Source: Business Wire]
OSLO, Norway-(BUSINESS WIRE)-The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company s growth, Dr. Kiprijanov (…)
[Read article]
[Source: BioSpace]
Mol Immunol. 2007 Mar 3; |-| Little M, Kipriyanov S. |-| Affimed Therapeutics AG, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.
[Read article]
[Source: NCBI PubMed]
Interleukin-13 (IL-13) is a T-cell-derived pleiotropic cytokine of particular medical importance because of its critical role in the development of allergic asthma. The effects of IL-13 on its target cells are mediated through a dimeric transmembrane receptor (IL-13R), which (…)
[Read article]
[Source: NCBI PubMed]
VANCOUVER, British Columbia & SCOTTSDALE, Ariz. & HEIDELBERG, Germany-(BUSINESS WIRE)-April 10, 2006-InNexus Biotechnology, Inc. (TSX.V: IXS)(OTCBB: IXSBF) and Affimed Therapeutics today announced a collaboration utilizing Affimeds antibodies and InNexus SuperAntibody antibody (…)
[Read article]
[Source: Business Wire]
BERLIN and HEIDELBERG, Germany, February 14 /PRNewswire/ - ProBioGen, the international cell specialists from Berlin, and Heidelberg based Affimed Therapeutics AG, specializing in the development of recombinant antibodies for the treatment of cancer, announce the execution of a (…)
[Read article]
[Source: PR Newswire]
To develop an effective antitumor immunotherapy for B-lineage non-Hodgkin s lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B-cell marker) and CD3 (T-cell antigen). Here, we report the effective killing of malignant primary B cells (…)
[Read article]
[Source: NCBI PubMed]
Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (V(H) and V(L) domains of two different specificities connected by three linkers. When assembled in the order V(H)(A)-linker(1)-V(L)(B)-linker(2)-V(H)(B)-linker(3)-V(L)(A), the (…)
[Read article]
[Source: NCBI PubMed]
Bispecific antibodies are currently in clinical and preclinical development for the treatment of various cancers. Designed to direct and enhance the body s immune response to specific tumors, bispecific antibodies consist of a targeting domain (typically an antibody fragment (…)
[Read article]
[Source: NCBI PubMed]
The mouse anti-human CD3 monoclonal antibody OKT3 is a potent immunosuppressive agent used in clinical transplantation. However, OKT3 therapy is associated with unpleasant and often serious side effects which appear to result from cytokine release, complement activation and a (…)
[Read article]
[Source: NCBI PubMed]
Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant (…)
[Read article]
[Source: NCBI PubMed]
Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (VH and VL) domains of two different specificities. Depending on the order of the VH and VL domains and on the length of peptides separating them, the single-chain molecule either (…)
[Read article]
[Source: NCBI PubMed]
Methods Mol Biol. 2003;207:3-25. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Heidelberg, Germany.
[Read article]
[Source: NCBI PubMed]
Methods Mol Biol. 2003;207:323-33. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Heidelberg, Germany.
[Read article]
[Source: NCBI PubMed]
To target NK cells against non-Hodgkin s lymphoma, we constructed a bispecific diabody (BsDb) with reactivity against both human CD19 and FcgammaRIII (CD16). Bacterially produced CD19 x CD16 BsDb specifically interacted with both CD19(+) and CD16(+) cells and exhibited (…)
[Read article]
[Source: NCBI PubMed]
Methods Mol Biol. 2002;178:333-41. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Ladenburg, Germany.
[Read article]
[Source: NCBI PubMed]
Methods Mol Biol. 2002;178:317-31. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Ladenburg, Germany.
[Read article]
[Source: NCBI PubMed]